The dominant genetic modifiers of NAFLD susceptibility and progression are the variants in patatin-like phospholipase domain-containing 3 (PNPLA3), transmembrane 6 superfamily member 2 (TM6SF2), membrane-bound O-acyltransferase domain-containing 7 (MBOAT7), glucokinase regulator (GCKR), and hydroxysteroid 17-beta dehydrogenase 13 (17β-HSD13) genes. The gene discussed is GCKR; the disease is metabolic dysfunction-associated steatotic liver disease.